Skip to product information
1 of 1

NorrChemica™

VI116 | Diazaborine 1 | Free-Acid Parent | ≥95%

VI116 | Diazaborine 1 | Free-Acid Parent | ≥95%

Regular price €65,00 EUR (incl. VAT)
Regular price Sale price €65,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Weight
Quantity

Technical Specifications

SMILES B1(C2=CC=CC=C2C=NN1S(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-])O
InChI InChI=1S/C13H10BN3O5S/c18-14-13-4-2-1-3-10(13)9-15-17(14)23(21,22)12-7-5-11(6-8-12)16(19)20/h1-9,18H
InChIKey OMIOMDKFWXJETP-UHFFFAOYSA-N
PubChem CID 177864762
Molecular Formula C13H10BN3O5S
Molecular Weight 331.11 g/mol
Solubility Soluble in DMSO, methanol, slightly soluble in chloroform.
Purity ≥95%
Physical Form White to yellow solid
HS Code 2934.99
Shelf Life Retest period: 36 months from date of manufacture
Storage Conditions Store in a cool, dry place in a tightly sealed container

Product Description & Scientific Applications

  • Identity: 4-nitrophenylsulfonyl benzodiazaborine, the free-acid parent compound (Diazaborine 1) of the series reported in Ilina et al., J. Med. Chem. 2026, 69, 3796–3810. The benzodiazaborine ring system fuses a benzene ring to a six-membered ring containing the B–N–N sequence, with an exocyclic B–OH and a 4-nitrobenzenesulfonyl group on the N2 nitrogen.
  • Position in the SAR series: VI116 is the simplest phenyl-series member: R¹ = H on the benzodiazaborine ring and R² = 4-nitrophenyl on the sulfonyl side chain. It is the structural reference for the SAR optimisation reported in the paper.
  • Relationship to the optimised lead: The most active compound in the paper (compound 11) differs from VI116 in two positions: a 3-methyl on the benzodiazaborine ring and a 3-aminophenyl on the sulfonyl side chain. Compound 11 shows MIC 6.25 μM against E. coli ATCC 25922, low cytotoxicity (HepG2 IC₅₀ 106 μM), synergy with colistin (FICI 0.25), and rescued Galleria mellonella larvae infected with E. coli at therapeutic doses of 1.13 and 2.81 mg/kg; the 2.81 mg/kg dose matched ciprofloxacin at 20 mg/kg.
  • Aqueous handling: The free-acid parent diazaborines in this series are barely soluble in water. The water and human-plasma stability experiments at 37 °C were therefore performed on the corresponding water-soluble salt forms; salt forms of compound 11 retained the same MIC as the parent. For aqueous-handling research applications, NorrChemica supplies VI706 (Diazaborine 62, sodium salt of compound 11) and VI880 (Diazaborine 64, sodium salt of compound 13) as separate catalogue items.
  • Mechanism of action of the diazaborine class: Diazaborines inhibit enoyl-acyl carrier protein reductase (FabI) by forming a covalent adduct between the boron atom and the 2′-hydroxyl of the ribose in the enzyme-bound NAD⁺ cofactor, evidenced by E. coli FabI crystal structures (PDB 5CG1, 5CG2; 2.07–2.2 Å). A disordered loop (Leu195–Met206 in E. coli) folds to cover the inhibitor site.
  • Reported profile of VI116: Compound 1 did not reach ≥50% growth inhibition of E. coli ATCC 25922 at 50 μM in the primary screening assay and was not included in the FabI inhibition subset. Its value as a catalogue item is as the parent SAR scaffold, not as a bioactive compound.
  • Research applications: Parent reference for SAR comparison within the benzodiazaborine scaffold; scaffold characterisation, biophysical, and computational studies; ¹¹B NMR reference for the benzodiazaborine ring system.
  • Class context: The benzodiazaborine ring is mechanistically distinct from cyclic boronate β-lactamase inhibitors approved or in clinical development (vaborbactam, FDA-approved 2017; taniborbactam and xeruborbactam in clinical development). Different target (FabI vs β-lactamases), different binding partner (NAD⁺ ribose vs active-site serine), different ring geometry. The original Sandoz diazaborine programme (Grassberger 1984, J. Med. Chem. 27, 947) was halted on intrinsic-toxicity concerns about boron, a position the modern boron-drug regulatory record reopens.
  • Documentation: ≥95% purity by ¹H NMR. CoA and SDS provided with each shipment. DDP shipping to EU, UK, EFTA, and worldwide locations.
  • Further reading: Scientific background on diazaborine FabI inhibitors and the water-soluble sodium-salt derivatives in NorrChemica's Lab Journal: Water-Soluble Diazaborines: Selective Gram-Negative Antibiotic Candidates for Synergy Studies and R&D.

Shipping Destinations

  • EU & UK: Priority delivery, 2–5 business days.
  • United States (DDP): 3–7 business days, duties and taxes prepaid.
  • EFTA Countries (DDP): 3–7 business days, duties and taxes prepaid.
  • Worldwide: 7–14 business days, selected locations.

The NorrChemica™ Standard

Identity Verified — Batch-verified via analytical QC; documentation available on request.

Direct EU Distribution — Dispatched from Finland for fast delivery to EU-based laboratories.

Professional Logistics — Tracked courier shipping via UPS / Matkahuolto / Posti.

Packaging & Storage

  • Supplied in tightly sealed containers suitable for laboratory handling.
  • Store under recommended conditions as specified on the product label and SDS.
  • Retest period per lot-specific CoA / label under recommended conditions.

Technical Documentation

  • Batch-specific Certificate of Analysis (CoA) included with every order.
  • GHS-compliant Safety Data Sheet (SDS) provided with every shipment.
  • Batch documentation available for institutional procurement.
Payment: Wise (Bank Transfer) or Manual Invoice.
Disclaimer: Research Use Only (RUO) — not for human or veterinary use. Sold strictly for laboratory research and technical applications. By purchasing this item, the buyer confirms professional intent and compliance with applicable regulations.

Safety Information

Hazard Class None — not subject to transport regulations
Transport Category Not classified as dangerous goods for transport (ADR/IATA/IMDG)

NorrChemica™ is a Finnish supplier of niche research reagents — focused on reliable EU distribution, transparent analytical documentation, and specialist technical support.

View full details